1. 1. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51.
2. 2. Pathirana D, Ormerod AD, Saiag P, et al.: European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):1-70. Erratum in: J Eur Acad Dermatol Venereol 2010;24:117-8.
3. 3. Chong BF, Wong HK: Immunobiologics in the treatment of psoriasis. Clin Immunol 2007;12:129-38.
4. : Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis;Nestorov;Br J Clin Pharmacol,2006
5. : A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis;Moore;J Am Acad Dermatol,2007